Introduction {#s1}
============

The global prevalence of diabetes is increasing \[[@R01]\], with also the incidence of associated cardiovascular (CV) death. Almost half of type 2 diabetic patients are reported to have hypertension during their lifetime \[[@R02]-[@R04]\]. The coexistence of hypertension and diabetes mellitus (DM) especially increases the risk of CV events, and hypertension represents the most important of all the prognostic factors for DM patients \[[@R05]\]. Upregulation of the renin-angiotensin-aldosterone system (RAAS) has been associated to the physiopathology of hypertension in DM patients \[[@R06]\]; therefore, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) represent the first choice antihypertensive drugs for these patients. While blood pressure (BP) control is reported to reduce CV events and associated mortality \[[@R07]-[@R9]\], antihypertensive monotherapy often proves inadequate with two-thirds of the patients with hypertension and requires two or more antihypertensive agents for BP control in clinical settings \[[@R10]-[@R12]\].

On the other hand, primary aldosteronism (PA) results from the oversecretion of aldosterone from the adrenal glands and represents one of the common causes of secondary hypertension. In recent years, PA has become increasingly diagnosed or detected due to clinical practice guidelines for PA becoming available \[[@R13], [@R14]\] and advances in imaging technology, and it is reported to account for 5-10% of all hypertension cases \[[@R15]-[@R18]\]. Delays in the diagnosis of PA are thought to lead to the onset of treatment-refractory hypertension, thus causing damage to such organs as the brain, CV system and kidneys \[[@R19]-[@R21]\]. It is crucial to take measures to ensure that PA is diagnosed and treated early since it can be cured with appropriate diagnostic and therapeutic measures.

It has been reported that 15-17% of PA patients have complications due to diabetes which are higher than the approximately 9% prevalence in the general population \[[@R22], [@R23]\]. However, to date, the clinical characteristics of PA patients with DM and their response to antihypertensive therapy remain less well characterized. Therefore, in this study, we have compared differences in BP control, use of antihypertensive agents and clinical characteristics between PA patients with and without DM.

Materials and Methods {#s2}
=====================

Patients and data collection {#s2a}
----------------------------

This study was submitted to the institutional review board at the Jikei University School of Medicine for review and approval as a retrospective observational study and approved (approval number 26-338).

The 114 patients diagnosed with PA were treated in an inpatient setting at our hospital between April 2008 and December 2014 and type 2 DM was defined according to the guidelines of the Japan Diabetes Society \[[@R24]\]. Patients were excluded if their BP or HbA1c were deficient and 18 patients were diagnosed as PA with DM. The study included a total of 70 patients. The 52 PA patients without DM who matched age and sex were chosen as a control group for this study ([Fig. 1](#F1){ref-type="fig"}).

![The study included a total of 70 patients. The 18 patients were diagnosed as PA with DM. As control group, 52 PA patients without DM who matched age and sex were chosen in this study. The central blood pressure was measured in 28 PA patients, including eight PA with DM and 20 PA without DM.](jocmr-10-056-g001){#F1}

Diagnosis of PA was conducted according to the Japan Endocrine Society guideline \[[@R16]\]. All patients being treated with ACE inhibitors, ARBs, mineralocorticoid receptor (MR) antagonists and β-blockers at initial presentation were switched to calcium channel blockers (CCBs) and α-blockers. Their medical records were examined for endocrine status, BP control, and use of therapeutic agents. BP was measured in the right arm in all patients while in a sitting position using sphygmomanometer (ADVANCE BP-203RVIIIC/D Omron Colin Inc., Tokyo, Japan) (Korotkoff I and V) and central BP (CBP) was measured using HEM 9000 AI (Omron Colin Inc., Tokyo, Japan). The BP was measured in the morning in the outpatient department before switching to CCBs and α-blockers.

Statistical analysis {#s2b}
--------------------

Continuous variables are presented as mean ± standard deviation and compared by analysis of variance, paired *t*-test, or Mann-Whitney U test, as appropriate. Pearson's correlation coefficients were used to examine correlations between two variables. A P value of \< 0.05 was considered significant in all analyses. All statistical analyses were performed using SPSS Statistics 22 (IBM Japan Inc., Tokyo, Japan).

Results {#s3}
=======

Clinical characteristics of patients with PA with and without DM {#s3a}
----------------------------------------------------------------

The PA patients with DM (DM+ group) or those without (DM- group) were compared for clinical characteristics ([Table 1](#T1){ref-type="table"}). The mean age of the DM+ group was 56.3 ± 8.3 years and the DM- group was 59.9 ± 9.1 years (P = 0.123). The DM+ group had 15 men and three woman and the DM- group had 37 men and 15 woman (P = 0.315). There were no significant differences in the BMI and hematological parameters between the groups.

###### Clinical Characteristics of 70 Patients With PA With and Without DM

                              PA with DM, mean ± SD   PA without DM, mean ± SD   *t*-test, P value
  --------------------------- ----------------------- -------------------------- -------------------
  N                           18                      52                         
  Age                         56.3 ± 8.3              59.9 ± 9.1                 0.123
  Sex (male/female)           15/3                    37/15                      0.315
  Body mass index (kg/m^2^)   26.4 ± 4.0              24.7 ± 3.9                 0.124
  HbA1c (%)                   7.5 ± 1.3               5.6 ± 0.4                  \< 0.001\*
  Duration of DM (years)      5.3 ± 6.2               \-                         
  PAC (pg/mL)                 210.0 ± 110.0           188.5 ± 125.7              0.521
  PRA (ng/mL/h)               0.57 ± 0.44             0.37 ± 0.33                0.050
  ARR                         891.4 ± 1231.9          835.5 ± 906.8              0.838
  ACTH (pg/mL)                25.6 ± 14.8             19.0 ± 10.6                0.053
  Cortisol (µg/dL)            13.4 ± 5.8              12.6 ± 4.1                 0.499
  Serum potassium (mEq/L)     3.7 ± 0.7               3.6 ± 0.6                  0.359
  Serum creatinine (mg/dL)    0.86 ± 0.19             0.80 ± 0.19                0.224
  eGFR (mL/min/1.73 m^2^)     71.3 ± 20.0             75.2 ± 16.7                0.422
  Triglyceride (mg/dL)        153.2 ± 69.7            129.1 ± 68.7               0.205
  HDL-cholesterol (mg/dL)     59.3 ± 28.4             55.4 ± 14.3                0.452
  LDL-cholesterol (mg/dL)     114.4 ± 33.9            117.8 ± 31.5               0.698

\*P \< 0.05. PAC: plasma aldosterone concentration; PRA: plasma renin activity; ARR: aldosterone-to-renin ratio.

The DM+ group had a mean HbA1c of 7.5±1.3%, a mean duration of diabetes of 5.3 ± 6.2 years, and a mean urinary C-peptide of 78.1 ± 48.4 µg/day and the insulin-secretory capacity was shown to be intact in all patients. Of the diabetic complications identified, simple diabetic retinopathy was found in five patients, urinary albumin excretion was found in 10 patients, diabetic neuropathy was found in four patients and no patients exhibited overt nephropathy. The treatments implemented for diabetes were diet therapy in two patients (11.1%) and anti-diabetic medications in 16 patients (88.9%) (insulin + oral hypoglycemic agents (OHAs), three patients (18.8%); OHAs, 13 patients (81.2%)).

The presence or absence of DM was examined for its influence on screening, the DM+ group was tended to have high plasma renin activity (PRA) and plasma aldosterone concentration (PAC) than the DM- group, but no significant difference in PRA, PAC and aldosterone-to-renin ratio (ARR), respectively.

BP and antihypertensive drugs of patients with PA with and without DM {#s3b}
---------------------------------------------------------------------

The DM+ and DM- groups were compared for BP control and antihypertensive drug use ([Table 2](#T2){ref-type="table"}). The patients changed their antihypertensive medications after their first presentation to the outpatient clinic to allow for a thorough inpatient workout, and the medications used in the outpatient setting were compared between the DM+ and DM- groups. There was no difference with regard to the duration of hypertension between the groups (9.7 ± 7.7 vs. 8.7 ± 8.9; P = 0.679). It took 9 years until PA was diagnosed after starting hypertensive treatment in both groups. While systolic BP and diastolic BP were found to be comparable between the groups, interestingly those in the DM+ group were found to have required significantly more antihypertensive agents than those in the DM- group (number of antihypertensive agents used, 2.0 ± 1.5 vs. 1.3 ± 1.1; P = 0.026; proportion of patients on three or more agents, 50% vs. 13%; P = 0.001, respectively). As a treatment of PA, a total of 21 patients (30.0%) underwent surgery. We evaluated the antihypertensive agents in the first outpatient department after PA treatment. We were able to reduce the antihypertensive agents in the operation case of the DM- group (1.9 ± 1.1 → 0.5 ± 1.0; P \< 0.001), but the hypertensive agents could not be decreased, even for surgically treated patients, in the DM+ group (2.8 ± 1.3 → 2.5 ± 2.1; P = 0.844).

###### Blood Pressure and Antihypertensive Drugs of Patients With PA With and Without DM

                                                        PA with DM, mean ± SD   PA without DM, mean ± SD   *t*-test, P value
  ----------------------------------------------------- ----------------------- -------------------------- -------------------
  N                                                     18                      52                         
  Duration of hypertension (years)                      9.7 ± 7.7               8.7 ± 8.9                  0.679
  Systolic BP (mm Hg)                                   148.1 ± 19.5            143.9 ± 18.3               0.533
  Diastolic BP (mm Hg)                                  87.7 ± 14.9             87.3 ± 11.6                0.907
  Number of antihypertensive drugs                      2.0 ± 1.5               1.3 ± 1.1                  0.026\*
  Antihypertensive drugs ≥ 3                            9 (50%)                 7 (13%)                    0.001\*
    CCB                                                 15 (83%)                36 (69%)                   0.252
    ARB                                                 6 (33%)                 8 (15%)                    0.104
    ACEI                                                2 (11%)                 1 (2%)                     0.100
    MR antagonist                                       1 (6%)                  2 (4%)                     0.762
    β-blocker                                           7 (39%)                 6 (12%)                    0.010\*
    α-blocker                                           1 (6%)                  8 (15%)                    0.290
    Diuretic drug                                       2 (8.0%)                3 (6%)                     0.455
    Vasodilator                                         1 (6%)                  0 (0%)                     0.089
  Treatment                                                                                                
    Operation                                           4 (22%)                 17 (33%)                   0.41
    MR blocker                                          13 (72%)                30 (58%)                   0.28
    Other                                               1 (6%)                  5 (9%)                     0.60
  Number of antihypertensive drugs after PA treatment                                                      
    Operation (+)                                       2.5 ± 2.1               0.5 ± 1.0                  0.095
    (-)                                                 2.3 ± 0.9               2.0 ± 1.1                  0.129

\*P \< 0.05. CCB: calcium channel blocker; ARB: angiotensin II receptor blocker; ACEI: angiotensin-converting enzyme inhibitor; MR: mineralocorticoid receptor.

CBP of 28 patients with PA with and without DM {#s3c}
----------------------------------------------

We examined the CBP of 28 PA patients, including eight PA with DM and 20 PA without DM ([Fig. 1](#F1){ref-type="fig"}, [Table 3](#T3){ref-type="table"}). CBP was tended to be higher in the DM+ group (151.0 ± 28.3 vs. 137.5 ± 13.7; P = 0.200). On the other hand, PAC was higher in DM+ group than in DM- group (240.3 ± 118.5 vs. 138.6 ± 48.6; P = 0.003). Furthermore, a correlation was shown between PAC and CBP (r = 0.583; P \< 0.001) ([Fig. 2](#F2){ref-type="fig"}). Multiple regression analyses in CBP were performed in a core model consisting of the following variables: age, sex and body mass index. PAC was independently associated with CBP (adjust R^2^ = 0.239; standardized coefficient β = 0.566, P \< 0.006) ([Table 4](#T4){ref-type="table"}).

###### Clinical Characteristics of 28 Patients for Whom Measured Central Blood Pressure

                                     PA with DM, mean ± SD   PA without DM, mean ± SD   *t*-test, P value
  ---------------------------------- ----------------------- -------------------------- -------------------
  N                                  8                       20                         
  Age                                65.0 ± 13.0             51.6 ± 10.8                0.009\*
  Sex (male/female)                  7/1                     5/15                       0.485
  Body mass index (kg/m^2^)          25.9 ± 5.0              24.9 ± 2.5                 0.496
  HbA1c (%)                          7.3 ± 1.3               5.44 ± 0.4                 \< 0.001\*
  PAC (pg/mL)                        240.3 ± 118.5           138.6 ± 48.6               0.003\*
  PRA (ng/mL/h)                      0.6 ± 0.4               0.5 ± 0.3                  0.611
  ARR                                530.2 ± 282.1           414.8 ± 297.3              0.356
  Duration of hypertension (years)   11.7 ± 9.1              7.7 ± 9.1                  0.343
  Central BP (mm Hg)                 151.0 ± 28.3            137.5 ± 13.7               0.200
  Systolic BP (mm Hg)                148.0 ± 18.7            143.9 ± 21.6               0.642
  Diastolic BP (mm Hg)               86.5 ± 13.4             87.7 ± 15.9                0.853

\*P \< 0.05. PAC: plasma aldosterone concentration; PRA: plasma renin activity; ARR: aldosterone-to-renin ratio.

![Correlation between PAC, ARR and CBP (based on CBP measurements). In the 28 PA patients for whom measured CBP values were available, a correlation was seen between PAC and CBP (r = 0.58; P \< 0.01).](jocmr-10-056-g002){#F2}

###### Multiple Regression Analysis of PAC With CBP

        Standardized coefficient (β)   P value   Adjust R^2^
  ----- ------------------------------ --------- -------------
                                                 0.239
  PAC   0.566                          0.006\*   
  Age   -0.021                         0.916     
  Sex   -0.096                         0.619     
  BMI   0.035                          0.851     

\*P \< 0.05.

Discussion {#s4}
==========

This study demonstrated that PA complicated by DM required more antihypertensive drugs than PA alone to achieve comparable BP control. Furthermore, in the 28 patients for whom CBP was measured, a positive correlation was shown between PAC and CBP.

It is becoming clear that patients with PA are more likely to be associated with more serious CV complications than patients with essential hypertension, when matched for severity and duration of hypertension \[[@R25]\]. In the RALES trial \[[@R26]\], as well as in the EPHESUS trial \[[@R27]\], the use of an MR antagonist as an add-on to cardiac failure management has been shown to improve prognosis and to be effective in preventing CV events. These report established aldosterone as an independent risk factor for the CV system and hyperaldosteronism is associated with advanced arteriosclerotic lesions and cardiac fibrosis \[[@R28], [@R29]\].

On the other hand, upregulation of the RAAS has been associated to the physiopathology of hypertension in DM patients \[[@R06], [@R30]\], and the Framingham study showed that patients with DM are at an approximately three-fold risk of developing CV events \[[@R31]\].

In this study, we examined the CBP of 28 PA patients. CBP represents BP at the aortic root and has been shown to be more strongly correlated with organ damage than peripheral BP \[[@R32], [@R33]\]. Tomaschitz et al have previously reported that CBP can be predicted from PAC excess and ARR level in patients undergoing coronary angiography \[[@R34]\]. As our result, a positive correlation was shown between PAC and CBP, and PAC was significantly higher in the PA with DM group. However, there was no correlation between ARR and CBP. For this reason, ARR is affected by several factors such as age, sex, plasma potassium concentration, body mass index, etc. \[[@R35]\] and PRA decreases in DM with hypertension patients with advanced diabetic complications \[[@R36]\].

The limitations of this study are: 1) small retrospective analysis of PA patients; 2) we examined the class of the antihypertensive agent but did not examine each dose amount and kind; and 3) though the duration of diabetes was short, 5.3 ± 6.2 years, we could not exclude the influence that diabetes may have had on the arteriosclerosis. Despite these limitations, the current report may be of particular interest in providing findings on PA complicated DM.

In summary, these results suggest that hypertension becomes more difficult to control in PA patients with DM.

Conclusions {#s4a}
-----------

PA complicated by DM requires more antihypertensive agents than PA alone to achieve comparable BP control and may be associated with more advanced arteriosclerosis.
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